![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
HG Joost, AD Habberfield, IA Simpson, A Laurenza and KB Seamon
Experimental Diabetes, Metabolism and Nutrition Section, MCNEB/National Institute of Arthritis, Bethesda, Maryland 20892.
Forskolin and four analogues of forskolin, 7-beta-[gamma-(N'- methylpiperazino)-butyryloxy]-7-desacet ylforskolin, 7- desacetylforskolin, 7-tosyl-7-desacetylforskolin, and 1,9- dideoxyforskolin, were tested for their ability to activate adenylate cyclase, inhibit glucose transport, and inhibit cytochalasin B binding in rat adipocyte membranes. Forskolin was the most potent analogue in activating adenylate cyclase with an EC50 of 2 microM, whereas 7-beta- [gamma-(N'-methylpiperazino)butyryloxy]-7-desacety lforskolin and 7- desacetylforskolin were less potent, with EC50 values of 3 microM and 20 microM, respectively. The 7-tosyl-7-desacetylforskolin and 1,9- dideoxyforskolin did not stimulate adenylate cyclase even at the highest concentrations tested (100 microM). In contrast, forskolin and all of the analogues were able to fully inhibit glucose transport in adipocyte plasma membranes. The order of potency for the inhibition was forskolin greater than 7-beta-[gamma-(N'-methylpiperazino)butyryloxy]-7- desacety lforskolin greater than 7-desacetylforskolin greater than 7- tosyl-7-desacetylforskolin greater than 1,9-dideoxyforskolin, and the EC50 values were 0.24 microM, 1.8 microM, 7.1 microM, 8.8 microM, and 12.8 microM, respectively. Cytochalasin B binding to rat adipocyte membranes was inhibited by forskolin and the four analogues with the same order of potency as observed for the inhibition of glucose transport. Thus, the site of action of forskolin which is responsible for the inhibition of glucose transport and cytochasin B binding exhibits structural requirements for forskolin and its analogues that are different from those of the site responsible for the activation of adenylate cyclase.
This article has been cited by other articles:
|
|
 |
|
  A. Salas-Burgos, P. Iserovich, F. Zuniga, J. C. Vera, and J. Fischbarg Predicting the Three-Dimensional Structure of the Human Facilitative Glucose Transporter Glut1 by a Novel Evolutionary Homology Strategy: Insights on the Molecular Mechanism of Substrate Migration, and Binding Sites for Glucose and Inhibitory Molecules Biophys. J., November 1, 2004; 87(5): 2990 - 2999. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Khanum, E. Buczko, and M. L. Dufau Essential Role of Adenosine Triphosphate in Activation of 17{beta}-Hydroxysteroid Dehydrogenase in the Rat Leydig Cell Endocrinology, April 1, 1997; 138(4): 1612 - 1620. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. P. Hayslett, L. J. Macala, J. I. Smallwood, L. Kalghatgi, J. Gassala-Herraiz, and C. Isales Vasopressin-stimulated Electrogenic Sodium Transport in A6 Cells Is Linked to a Ca[IMAGE]-mobilizing Signal Mechanism J. Biol. Chem., July 7, 1995; 270(27): 16082 - 16088. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Tang and A. Gilman Construction of a soluble adenylyl cyclase activated by Gs alpha and forskolin Science, June 23, 1995; 268(5218): 1769 - 1772. [Abstract] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
